VAT1

Chr 17

vesicle amine transport 1

Also known as: MIB, VAT-1, VATI

VAT1 encodes a multifunctional protein that functions as a NADPH-dependent quinone oxidoreductase and mediates transfer of negatively charged phospholipids between endoplasmic reticulum and mitochondrial membranes, while also regulating mitochondrial fusion through interaction with mitofusins. The gene has a low probability of loss-of-function intolerance (pLI = 0.005) and high loss-of-function observed/expected upper bound fraction (LOEUF = 0.837), with pathogenic variants predicted to act through a gain-of-function mechanism. No specific neurogenetic diseases have been definitively associated with VAT1 mutations in the provided data.

Summary from RefSeq, UniProt, Mechanism
0
Active trials
6
Pubs (1 yr)
6
P/LP submissions
0%
P/LP missense
0.84
LOEUF
GOF
Mechanism· predicted
Clinical SummaryVAT1
Population Constraint (gnomAD)
Low constraint (pLI 0.01) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
6 unique Pathogenic / Likely Pathogenic· 52 VUS of 70 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.84LOEUF
pLI 0.005
Z-score 2.01
OE 0.42 (0.230.84)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
1.41Z-score
OE missense 0.74 (0.660.84)
176 obs / 237.3 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.42 (0.230.84)
00.351.4
Missense OE0.74 (0.660.84)
00.61.4
Synonymous OE1.00
01.21.6
LoF obs/exp: 6 / 14.2Missense obs/exp: 176 / 237.3Syn Z: 0.01
DN
0.6454th %ile
GOF
0.7125th %ile
LOF
0.2970th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

70 submitted variants in ClinVar

Classification Summary

Pathogenic6
VUS52
Likely Benign1
Benign1
6
Pathogenic
52
VUS
1
Likely Benign
1
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
6
0
6
Likely Pathogenic
0
0
0
0
0
VUS
0
50
2
0
52
Likely Benign
0
1
0
0
1
Benign
0
1
0
0
1
Total0528060

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

VAT1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →